Vertex Pharmaceuticals

VRTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$559.41

+$19.41 (+3.59%)

At close: Oct 30, 2026, 4:00 PM ET

$559.00

-$0.41 (-0.07%)

Pre-market: Nov 2, 2026, 8:18 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.59%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

64.6

-1.0 pts

Fundamentals Strong

Market Sentiment Neutral

Moat Wide

Sector Rank #99/1028 (Top 10%)

Full Analysis

Why Price Moved

2 months ago

-3.15%

Vertex Pharmaceuticals stock declined as investors...

Key Statistics

Market Data

Market Cap $141.79B

1D Range

549.89 563.80

52W Range

409.47 563.80

Valuation (TTM)

PE 32.56

PB 7.00

EV/EBITDA 24.60

Valuation (NTM)

Forward PE 27.23

Forward PEG 25.55

Price Target $573.50

Cash Flow

FCF Yield 2.7%

SBC Adj. FCF Yield 2.2%

SBC Impact -18.1%

Margins

Gross Margin 86.0%

Operating Margin 38.6%

FCF Margin 30.1%

Growth (CAGR)

Revenue 3Y | 5Y 9.9% | 13.6%

Dil EPS 3Y | 5Y 9.9% | 17.8%

FCF 3Y | 5Y -0.7% | 16.4%

Returns

ROA 16.1%

ROE 23.3%

ROIC 17.3%

Financial Health

Net Cash

$7.85B

Current Ratio 3.19

Interest Coverage 738.18

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The ...

Sector Healthcare

Industry Biotechnology

Employees 6,400

IPO Date Jul 24, 1991

Website www.vrtx.com

Fiscal Year January - December

Full Company Profile

Latest News

5 days ago · zacks.com

Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Evaluate the expected performance of Vertex (VRTX) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

5 days ago · zacks.com

Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

6 days ago · zacks.com

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.

7 days ago · zacks.com

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 days ago · seekingalpha.com

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript

10 days ago · businesswire.com

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details a.

13 days ago · zacks.com

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $514.7 in the latest trading session, marking a +2.54% move from the prior day.

Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?

17 days ago · zacks.com

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.